News and Trends 27 Apr 2017 Heptares Finds New GPCR Target to Treat Pain, Cancer and Inflammation Heptares Therapeutics has published the detailed structure and mechanism of action of a difficult-to-target GPCR protein with great therapeutic prospects. Heptares Therapeutics has published today in Nature new insights into the mechanism of action of antagonists of the protease-activated receptor 2 (PAR2), a molecule involved in metabolism and inflammatory responses. The study is part of […] April 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Apr 2017 BRIEF: Dutch Biotech Goes for MAA in the EU with new Immunotherapy Kiadis Pharma has applied for marketing authorization from the EMA for its T cell immune therapy, which could halt graft-versus-host disease (GVHD). Kiadis‘ MAA with the EMA doesn’t come as a surprise. After the EMA recently accepted the Biotech’s Pediatric Investigation Plan for its lead product ATIR101, the MAA was just a matter of time. Based in Amsterdam, […] April 26, 2017 - 1 minutemin - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 25 Apr 2017 Novartis Negotiates its Way into the US Migraine Market Amgen and Novartis have expanded their collaboration for the co-development of their migraine drug, ensuring Novartis will get a chunk of the US revenues. After Novartis and Amgen recently completed their second Phase III study for their migraine drug erenumab, the companies have now reworked their commercial partnership. The two pharma giants teamed up back in 2015 to co-develop […] April 25, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 25 Apr 2017 EMA designates uniQure’s gene therapy for hemophilia a priority Following a Breakthrough Designation from the FDA earlier this year, the Dutch biotech has scored the European equivalent for AMT-060. Since its claim to fame, Glybera, fell from grace to become a commercial failure, uniQure has been on the rebound. The company recently has undergone several management shakeups and a strategy review, and it just made the decision to withdraw […] April 25, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 25 Apr 2017 New Research could Save Patients from Graft-Versus-Host Disease A new study published in the journal Science Translational Medicine identifies a new treatment strategy to prevent GVHD after stem cell transplantation. Allogeneic stem cell transplantation remains one of the top treatments for blood cancers and inherited blood disorders, but the treatment is associated with a major risk of so-called graft-versus-host disease (GVHD). A new paper […] April 25, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 24 Apr 2017 Genfit Delays Phase III Enrollment in the Race for the First NASH Therapy Genfit has announced that closing of enrollment will be delayed up to 6 months. Will this affect its chances to be the first to launch a treatment for NASH? The French biotech Genfit is leading the race to launch the first treatment ever for non-alcoholic steatohepatitis (NASH), a liver disease that affects 30 million people worldwide and has […] April 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 22 Apr 2017 Art Made with CRISPR Aims to Raise Awareness of Antibiotic Resistance Anna Dumitriu’s latest bioart piece is a historic dress carrying bacteria genetically modified using CRISPR and opens the debate on antibiotic resistance. A wartime women’s suit is the canvas where Anna Dumitriu paints the history of antibiotics. The holes and stains in the suit are patched and embroidered with silk that has been dyed with E. […] April 22, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Apr 2017 The World’s Most Expensive Drugs have European Owners A new report has listed the world’s most expensive drugs. Not surprisingly, those targeting rare diseases bear the heaviest price tags – let’s have a look. While biotechs like Généthon and EspeRare are rethinking the high-risk high-profit model and looking to provide treatments at an affordable price, most rare disease meds on the market are among the most […] April 21, 2017 - 4 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 21 Apr 2017 Fungi Genomes could be a Gold Mine of New Antibiotics Good old Penicillium still has a lot more tricks upon its sleeve: Swedish researchers see its potential as a gold mine for new antibiotics. The genomic analysis of Penicillium species represents a potential gold mine for new bioactive compounds, or improved versions of those we already use. Published recently in Nature Microbiology, the work was carried at Chalmers University […] April 21, 2017 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 20 Apr 2017 Goodbye Glybera! The World’s First Gene Therapy will be Withdrawn The excitement about the therapy was undercut when it became clear Glybera would be a commercial failure. In October, it will officially be dead. uniQure has announced that it will not go for the renewal of its marketing authorization for Glybera in Europe, which is set to expire in October this year. Since Glybera missed approval in the […] April 20, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 20 Apr 2017 Norway Brings Another Cancer Vaccine to the Clinic Targovax has recruited its first patient in a Phase Ib trial for its new cancer vaccine TG02 targeting mutations of the RAS gene. Mutations of the RAS gene disrupt normal cell division and are a key driver of cancer progression and treatment resistance. The Norwegian biotech Targovax is developing peptide-based anti-cancer vaccines targeting these mutations found […] April 20, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 20 Apr 2017 New French Biotech Seed Fund Raises €65M in its First Closing Advent France Biotechnology has launched its first seed fund for Life Sciences with the support of Bpifrance and Advent Life Sciences. Advent France Biotechnology, founded in 2015, has exceeded its initial fundraising target at the first closing. Its Seed-Fund I now counts with €64.75M that will be invested predominantly in France. The funds will back entrepreneurs […] April 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email